Impact of hepatitis B core antibody (anti HBc) seropositivity on interferon/ribavirin treatment response in patients with chronic hepatitis C.
AntiHBc seropositivity among patients with chronic HCV infection is not a rare entity (57.14 %). We observed that antiHBc antibody seropositivity does not have a significant impact on treatment responses to interferon/ribavirin therapy in patients for chronic HCV infection in contrast to some reports in the literature (Tab. 6, Ref. 39) Full Text (Free, PDF) www.bmj.sk.